Jump to content
Advertisement

Advertisement

Search the Community

Showing results for 'DDW19' in content posted in General Discussion.


Didn't find what you were looking for? Try searching for:


More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Community

  • Discussion
    • Welcome!
    • Podcasts
    • General Discussion
    • Diarrhea predominant Irritable Bowel Syndrome (IBS-D), Post-Infectious IBS (PI-IBS) and Leaky Gas (LG), Incontinence or Odor.
    • Constipation predominant Irritable Bowel Syndrome (IBS-C) and Chronic Idiopathic Constipation (CIC)
    • Diet and FODMAP Diet
    • Medications, Medical Foods and Fecal Microbiota Transplantation (FMT)
    • IBS Patient Diaries
    • Clinical Research Trials
    • IBS News Articles and Research Results
    • IBS Newsfeed
    • IBS Twitter feed
    • We Remember
    • Announcements

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 36 results

  1. Drossman: Evidence that there may be brain cell death due to the vicious cycle of pain from FGID (Functional Gastrointestinal) condition. Drossman: Validate symptoms, explain thoroughly, & don’t abandon your patients. Chey: Shared “Advice from a patient” from J Ruddy Gastroenterology 2018 Chey: Non-verbal communication is incredibly important in approaching a patient. It gives hope and trust. Chey: We’re still learning about the genetic factors behind IBS Chey: How I describe IBS to patients. With hope, trust and confidence. Chey: Role of Stress & Anxiety in GI Disorders. Anxiety... Is this a chicken and egg situation?? “It’s not all in your head but your head may be playing a role in your symptoms” Chey: Post-infectious IBS (PI-IBS), are we giving patient hope or taking it away? Chey: Potty talk. How you can talk to patients about pooping. Chey: Rodin’s “The Thinker” might just be the perfect position to have a good bowel movement! Chey: Create a spirit of collaboration. “What matters is what the patient takes away from you.” Chey: Give your patients hope.
  2. A Bug's World: The Microbiome in Gastrointestinal Conditions Chair: William Chey, MD, Nostrant professor of gastroenterology & nutrition, University of Michigan Health System Speakers: Mark Pimental, MD, asst professor of medicine & exec director, David Geffen School of Medicine & Cedars-Sinai; Mille Long, MD, associate professor of medicine , University of North Carolina; Brennan Spiegel, MD, professor of medicine & public health director, Cedars-Sinai Health System Supported by Salix Pharmaceutical Altered microbiome leads to 2 gases, CH4 (methane) which leads to constipation and H2S (hydrogen sulphide) which lets to diarrhea Proposed IBS Pathophysiologic Sequence related to altered microbiome
  3. Camilleri: The Leaky Gut - What does it mean? Should I treat it? Is it treatable? Camilleri: Pitfalls and precautions in attributing relevance to “leakiness” of barrier. We need real research and data as there is insufficient data to support this diagnosis or treatment.
  4. Exposure to pets perhaps a factor in developing IBS says the team at East Tennessee State University Oh, Poop! Study Links Pets to Higher IBS Risk for Owners Possible reasons: microbiome-disrupting poop exposure; common thread of anxiety/depression by Randy Dotinga, Contributing Writer, MedPage Today May 19, 2019 SAN DIEGO -- Four-legged furballs may boost the risk for irritable bowel syndrome (IBS), and exposure to canine and feline feces could be a crucial factor, researchers reported here. In a meta-analysis of five studies, participants who were exposed to a variety of kinds of pets faced an odds ratio 1.26 (95% CI 1.018-1.569) of IBS, according to Laith Al Momani, MD, Ankit Patel, both of East Tennessee State University (ETSU) in Johnson City, and colleagues. "The odds ratio isn't huge. But with the prevalence of IBS, this can affect a lot of people," said Patel, an ETSU medical student, at the annual Digestive Disease Week. © 2019 MedPage Today, LLC >> Full story: https://www.medpagetoday.com/meetingcoverage/ddw/79919
  5. Chey: non-celiac responders to gluten is a subset group of patients Chey: Numerous RCT’s (randomized control trials) for low FODMAP most consistently for pain and bloating Chey: low FODMAP diet real live data is different than clinical trials as we don’t know long term elimination and reintroduction Chey: FODMAP Elimination is the beginning, not the end! Great message for all these doctors to hear. It’s a *process*, not just a list of low-FODMAP foods. See https://www.ibspatient.org/lowfodmap/ for more info. Chey: Can we utilize the microbiome to indicate who will do well on the low FODMAP diet for IBS? Chey: Fecal microbiome predicts IBS patients response to a low FODMAP diet Chey: Congenital Sucrase-isomaltese deficiency (CSID) is under diagnosed in IBS-D patients Chey: Supplementation (prebiotic) had same response as low FODMAP diet. Suggest that it might be beneficial in some patients eg: Glutamine for PI-IBS (post infectious IBS) Chey: Dietary manipulation is a critical part of the treatment strategy in patients with IBS. Food is complicated. Caterina Oneto: Several trials have shown the benefit of low #FODMAP diet in #IBS . Mechanism not entirely clear, but we do know that the low FODMAPs diet is associated with a) decreased total bacterial abundance and b) increased microbial diversity Premysl Bercik: Bacterial production of histamine may be an important factor in mechanism behind the benefit of a low FODMAP diet in reducing pain in IBS Shanti Eswaran: Reports lower response to low FODMAP diet in IBS patients with sucrase isomaltase gene defects. Something to consider in low FODMAP Diet non-responders.
  6. G. Leite (Cedars-Sinai) First Large Scale Study Microbiome Signatures #SIBO #REIMAGINE STUDY G. Leite: profile looked at all segments of small bowel. Compared profile for different conditions by sequencing G. Leite: Microbiome profile was found to be different between SIBO and non-SIBO G. Leite: #SIBO is associated with hydrogen production pathways G. Leite: Increased Proteobacteria phylum representation. associated with methane. M. Pimentel: Conclusive evidence for SIBO using deep sequencing in the REIMAGINE study. We now know who's the culprit! Enterobacteriaceae.
  7. Salix Pharmaceuticals Pledges Annual $100,000 Scholarship Program To Outstanding Students Living with GI Disease In Honor of Salix's 30-Year Anniversary, Salix Will Award 10 Recipients Up to $10,000 Each NEWS PROVIDED BY Salix Pharmaceuticals, Ltd. May 17, 2019, 09:13 ET BRIDGEWATER, N.J., May 17, 2019 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that it will launch the Salix Gastrointestinal Health Scholars Program, a new, annual scholarship program designed to provide financial support to outstanding students living with GI disease, as they pursue their higher education goals. The Salix Gastrointestinal Health Scholars Program will award 10 recipients, including students pursuing undergraduate or graduate degrees, up to $10,000 each. The commitment is part of a series of Salix-related announcements taking place at Digestive Disease Week® (DDW), the world's largest meeting of GI healthcare professionals. "The Salix Gastrointestinal Health Scholars is aimed at providing financial support to outstanding students who have not allowed GI disease to stand in the way of their academic achievements. We're proud to support these high achievers as they continue their studies," said Mark McKenna, president, Salix Pharmaceuticals. Salix plans to open applications for the Salix Gastrointestinal Health Scholars Program in the fall of 2019 and fulfill its commitment of awarding 10 recipients starting in the spring of 2020. Winners will be announced annually by Salix at DDW beginning in 2020. About Salix Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2019 Salix Pharmaceuticals or its affiliates. SAL.0079.USA.19 SOURCE Salix Pharmaceuticals, Ltd. Related Links http://salix.com https://www.prnewswire.com/news-releases/salix-pharmaceuticals-pledges-annual-100-000-scholarship-program-to-outstanding-students-living-with-gi-disease-300852411.html
  8. I was diagnosed with IBS in 2013. My first gastroenterologist tested me for everything as well, except for the breath test. Years passed, I moved and got a new gastroenterologist and wanted to see what he'd recommend for me. I tried a variety of things starting with bentyl, to rifaximin, then to an anti-depressant (elavil). None of the treatements worked for me. Over the years I learned to cope with sticking to the low FODMAP diet. There was an event that occurred when I traveled to Vietnam and got a gut infection and a viral infection. The doctors there prescribed metronidazole + probiotics. After my antibiotic course was completed, my gut and body were transformed for ~2 1/2 months. I was able to digest everything without any issues (bloating, loose stool) whatsoever. I could tell I was absorbing nutrients better too because I felt way stronger and extremely happy. Unfortunately my IBS returned after ~2 1/2 months. Since I felt like myself pre-IBS during that 2 1/2 months, I wanted to try other methods to try to cure IBS. I enrolled in a clinical trial for FMT for IBS-D patients. Some were randomized into an antibiotic pre-treatment arm, as I was. Then, FMT was administered via (19!) capsules. My outcome weeks later was actually worse than prior to the trial, which is a bit consistent with the meta-analyses (https://www.ibspatient.org/community/topic/18897-fecal-microbiota-transplantation-fmt-for-ibs-ddw19/?tab=comments#comment-19374). Anyway, I went on a long rant. For awhile I thought I might have SIBO since I had never taken the breath test to confirm, but I had taken 2-3 courses of rifaximin in the past that didn't impact my IBS symptoms at all. Thanks for sharing all of the presentations! We are still learning about the microbiome and IBS, and I think there will be a cure for IBS in my lifetime...
  9. Olorinab Reduces Visceral Hypersensitivity in Animal Models (DDW19)
×
×
  • Create New...